- TFF Pharmaceuticals Inc to Host Conference Call TranscriptDec 19, 2023
- Q3 2023 TFF Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2023$5.95 (+8.14%)Earnings
- Q2 2023 TFF Pharmaceuticals Inc Earnings Call TranscriptAug 15, 2023$10.25 (-8.89%)Earnings
- TFF Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- TFF Pharmaceuticals Inc To Host Investor Call TranscriptFeb 16, 2023
- Q3 2022 TFF Pharmaceuticals Inc Earnings Call TranscriptNov 14, 2022$37 (-12.43%)Earnings
- Q2 2022 TFF Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2022$154.25 (-2.37%)Earnings
- Q1 2022 TFF Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2022$99.75 (-5.00%)Earnings
- Q4 2021 TFF Pharmaceuticals Inc Earnings Call TranscriptMar 24, 2022$162.25 (-1.96%)Earnings
- TFF Pharmaceuticals Inc Science Day TranscriptDec 13, 2021
- Q3 2021 TFF Pharmaceuticals Inc Earnings Call TranscriptNov 15, 2021$174 (-4.79%)Earnings
- TFF Pharmaceuticals Inc Benzinga Global Small Cap Conference 2021 TranscriptOct 29, 2021
- TFF Pharmaceuticals Inc at SNN Network Summer Event (Virtual) TranscriptAug 19, 2021
- Q2 2021 TFF Pharmaceuticals Inc Earnings Call TranscriptAug 12, 2021$193.5 (+2.11%)Earnings
- Q1 2021 TFF Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2021$212 (-6.81%)Earnings
Q2 2023 TFF Pharmaceuticals Inc Earnings Call Transcript
Good morning, Ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.
I will now turn the call over to your host, Corey Davis of LifeSci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. With me on the line this afternoon are Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals; Dr. Zamaneh Mikhak, Chief Medical Officer; and Kirk Coleman, Chief Financial Officer.
Before we get started, I would like to remind everyone that this call will contain forward-looking statements, including, without limitation, statements about the anticipated timing of achievement of clinical milestones, the potential to see positive effects in our Phase II studies, the number of treated patients necessary to make our decisions in regards to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)